ABSTRACT
The above studies suggest that non-invasive tests may some day accurately detect plaque vulnerability. Findings in both epidemiologic studies and in ACS reflect different manifestations of CAD and may also represent a new pathway or triggering of destabilization in human atheroma, though morphologic plaque studies are needed. Because no vulnerable test yet has high sensitivity or specificity, using multiple markers simultaneously may augment these.
